Effects of ezetimibe/simvastatin and rosuvastatin on oxidative stress in diabetic neuropathy: A randomized, double-blind, placebo-controlled clinical trial

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Villegas Rivera, Geannyne ^a   Román Pintos, Luis Miguel ^b   Cardona Muñoz, Ernesto Germán ^b   Arias Carvajal, Oscar ^b   Rodríguez Carrizalez, Adolfo Daniel ^b   Troyo Sanromán, Rogelio ^b   Pacheco Moisés, Fermín Paul ^b   Moreno Ulloa, Aldo ^c,d   Miranda Díaz, Alejandra Guillermina ^b  

^a Instituto de Investigación Clínica de Occidente S A de C V   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; OXIDATIVE STRESS;

ADULT PATIENTS; AFTER-TREATMENT; DIABETIC NEUROPATHY; LIPID PEROXIDATION; METABOLIC PARAMETERS; NERVE CONDUCTION STUDY; NON-PARAMETRIC ANALYSIS; TYPE 2 DIABETES MELLITUS;

PATIENT TREATMENT;

BILIRUBIN; CHOLESTEROL; EZETIMIBE PLUS SIMVASTATIN; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PLACEBO; ROSUVASTATIN; TRIACYLGLYCEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATIGUE; FEMALE; HEADACHE; HICCUP; HUMAN; HYPERSOMNIA; LIPID PEROXIDATION; MALE; METABOLIC PARAMETERS; MIDDLE AGED; MYALGIA; MYOPATHY; NAUSEA; NERVE CONDUCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; CLINICAL TRIAL; DIABETIC NEUROPATHIES;

DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; EZETIMIBE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; ROSUVASTATIN CALCIUM; SIMVASTATIN;

EID: 84939171665     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/756294     Document Type: Article

References (35)

1. P. J. Dyck, K. M. Kratz, J. L. Karnes et al. , "The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester diabetic neuropathy study, " Neurology, vol. 43, no. 4, pp. 817-824, 1993.
2. Z. A. Kamenov and L. D. Traykov, "Diabetic somatic neuropathy, " Advances in Experimental Medicine and Biology, vol. 771, pp. 155-175, 2012.
3. P. J. Dyck, "Detection, characterization, and staging of polyneuropathy: assessed in diabetics, " Muscle and Nerve, vol. 11, no. 1, pp. 21-32, 1988.
4. P. J. Dyck and C. Giannini, "Pathologic alterations in the diabetic neuropathies of humans: a review, " Journal ofNeuropathology and Experimental Neurology, vol. 55, no. 12, pp. 1181-1193, 1996.
5. A. M. Vincent, M. Brownlee, and J. W. Russell, "Oxidative stress and programmed cell death in diabetic neuropathy, " Annals of the New York Academy of Sciences, vol. 959, pp. 368-383, 2002.
6. A. M. Vincent, J. W. Russell, P. Low, and E. L. Feldman, "Oxidative stress in the pathogenesis of diabetic neuropathy, " Endocrine Reviews, vol. 25, no. 4, pp. 612-628, 2004.
7. J. W. Russell, D. Golovoy, A. M. Vincent et al. , "High glucoseinduced oxidative stress and mitochondrial dysfunction in nuerons, "TheFASEB Journal, vol. 16, no. 13, pp. 1738-1748, 2002.
8. The Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus, " The New England Journal of Medicine, vol. 329, no. 14, pp. 977-986, 1993.
9. "Intensive blood-glucose controlwith sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, " The Lancet, vol. 352, no. 9131, pp. 837-853, 1998.
10. F. Ismail-Beigi, T. Craven, M. A. Banerji et al. , "Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial, " The Lancet, vol. 376, no. 9739, pp. 419-430, 2010.
11. A. M. Vincent, L. M. Hinder, R. Pop-Busui, and E. L. Feldman, "Hyperlipidemia: a newtherapeutic target for diabetic neuropathy, " Journal of the Peripheral Nervous System, vol. 14, no. 4, pp. 257-267, 2009.
12. T. D. Wiggin, K. A. Sullivan, R. Pop-Busui, A. Amato, A. A. F. Sima, and E. L. Feldman, "Elevated triglycerides correlate with progression of diabetic neuropathy, " Diabetes, vol. 58, no. 7, pp. 1634-1640, 2009.
13. A. Girach, D. Manner, and M. Porta, "Diabetic microvascular complications: can patients at risk be identified? A review, " International Journal of Clinical Practice, vol. 60, no. 11, pp. 1471-1483, 2006.
14. M. Pande, J. Hur, Y. Hong et al. , "Transcriptional profiling of diabetic neuropathy in the BKS db/dbmouse: a model of type 2 diabetes, " Diabetes, vol. 60, no. 7, pp. 1981-1989, 2011.
15. F. Taylor, M. D. Huffman, A. F. Macedo et al. , "Statins for the primary prevention of cardiovascular disease, " Cochrane Database of Systematic Reviews, vol. 1, Article ID CD004816, 2013.
16. J. K. Liao and U. Laufs, "Pleiotropic effects of statins, " Annual Review of Pharmacology and Toxicology, vol. 45, pp. 89-118, 2005.
17. T. M. E. Davis, B. B. Yeap, W. A. Davis, and D. G. Bruce, "Lipidlowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study, " Diabetologia, vol. 51, no. 4, pp. 562-566, 2008.
18. F. Franzoni, A. Quinones-Galvan, F. Regoli, E. Ferrannini, and F. Galetta, "A comparative study of the in vitro antioxidant activity of statins, " International Journal of Cardiology, vol. 90, no. 2-3, pp. 317-321, 2003.
19. N. Grosser, K. Erdmann, A. Hemmerle et al. , "Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1, " Biochemical and Biophysical Research Communications, vol. 325, no. 3, pp. 871-876, 2004.
20. U. Resch, F. Tatzber, A. Budinsky, and H. Sinzinger, "Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy, " British Journal of Clinical Pharmacology, vol. 61, no. 3, pp. 262-274, 2006.
21. J. D. England, G. S. Gronseth, G. Franklin et al. , "Distal symmetric polyneuropathy: a definition for clinical research-report of theAmericanAcademy ofNeurology, theAmericanAssociation of ElectrodiagnosticMedicine, and the AmericanAcademy of PhysicalMedicine and Rehabilitation, " Neurology, vol. 64, no. 2, pp. 199-207, 2005.
22. B. C. Callaghan, H. T. Cheng, C. L. Stables, A. L. Smith, and E. L. Feldman, "Diabetic neuropathy: clinical manifestations and current treatments, "The Lancet Neurology, vol. 11, no. 6, pp. 521-534, 2012.
23. C. E. Argoff, B. E. Cole, D. A. Fishbain, and G. A. Irving, "Diabetic peripheral neuropathic pain: clinical and quality-oflife issues, " Mayo Clinic Proceedings, vol. 81, no. 4, supplement, pp. S3-S11, 2006.
24. A. I. Vinik and A. Mehrabyan, "Diabetic neuropathies, " Medical Clinics of North America, vol. 88, no. 4, pp. 947-999, 2004.
25. A. Clemens, E. Siegel, and B. Gallwitz, "Global risk management in type 2 diabetes: blood glucose, blood pressure, and lipids-update on the background of the current guidelines, " Experimental and Clinical Endocrinology and Diabetes, vol. 112, no. 9, pp. 493-503, 2004.
26. N. Zangiabadi, K. Shafiee, K. H. Alavi, A. R. Assadi, and M. Damavandi, "Atorvastatin treatment improves diabetic polyneuropathy electrophysiological changes in non-insulin dependent diabetic patients: a double blind, randomized clinical trial, " Minerva Endocrinologica, vol. 37, no. 2, pp. 195-200, 2012.
27. E. Niki, "Lipid peroxidation products as oxidative stress biomarkers, " BioFactors, vol. 34, no. 2, pp. 171-180, 2008.
28. B. Halliwell and S. Chirico, "Lipid peroxidation: itsmechanism, measurement, and significance, " American Journal of Clinical Nutrition, vol. 57, no. 5, 1993.
29. M. Koksal, M. A. Eren, M. N. Turan, and T. Sabuncu, "The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients, "EuropeanJournal of InternalMedicine, vol. 22, no. 3, pp. 249-253, 2011.
30. G. Yoshino, M. Tanaka, S. Nakano et al. , "Effect of rosuvastatin on concentrations of plasma lipids, urine and plasma oxidative stress markers, and plasma high-sensitivity C-reactive protein in hypercholesterolemic patients with and without type 2 diabetes mellitus: a 12-week, open-label, pilot study, " Current Therapeutic Research: Clinical and Experimental, vol. 70, no. 6, pp. 439-448, 2009.
31. J. Girona, A. E. La Ville, R. Sola, N. Plana, and L. Masana, "Simvastatin decreases aldehyde production derived from lipoprotein oxidation, "The American Journal of Cardiology, vol. 83, no. 6, pp. 846-851, 1999.
32. M. A. Creager, T. F. Luscher, F. Cosentino, and J. A. Beckman, "Diabetes and vascular disease. Pathophysiology, clinical consequences, and medical therapy: part I, " Circulation, vol. 108, no. 12, pp. 1527-1532, 2003.
33. P.-Y. Liu, Y.-W. Liu, L.-J. Lin, J.-H. Chen, and J. K. Liao, "Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on Rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation, " Circulation, vol. 119, no. 1, pp. 131-138, 2009.
34. S. John, M. P. Schneider, C. Delles, J. Jacobi, and R. E. Schmieder, "Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients, " American Heart Journal, vol. 149, no. 3, pp. 473. e1-473. e10, 2005.
35. K. K. Koh, M. J. Quon, S. H. Han et al. , "Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients, " Diabetes Care, vol. 31, no. 4, pp. 776-782, 2008.